Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg |
ln Vitro |
Quinidine hydrobromide is an antiarrhythmic medication that modifies myocardial ionic currents and has been demonstrated to be a strong blocker of various K+ channel classes in a variety of cell types [1]. Ik peak amplitude decreases in a dose-dependent manner with quinidine hydrobromide bath treatment. It is calculated that at 0 mV, the Kd for Ik blockage is 41 μM [1]. Membrane depolarization amplifies the dose-dependent rise in Ik decay rate induced by quinidine hydrobromide. Quinidine also lengthens the half-life of inactivation recovery and induces a 5 mV hyperpolarizing change in the steady-state inactivation curve. When measured at -30 mV, quinidine hydrobromide had no effect on the beginning of inactivation [1].
|
---|---|
ln Vivo |
Quinidine hydrobromide is quickly absorbed; 60 to 90 minutes after oral dosing, the plasma concentration reaches its peak. Other salts, such as polygalacturonate and gluconate, have lower peak concentrations and are absorbed more slowly [2]. About 70–90% of quinidine hydrobromide is bound to plasma proteins. In the liver, it goes through oxidative metabolism to produce N-oxide, 3-hydroxy, O-desmethyl, and 2'-quinidinone [2]. In rats, quinidine hydrobromide slows the metabolism of amphetamines. Quinidine hydrobromide pretreatment led to a large rise in amphetamine excretion to 542% between 24 and 48 hours, and a significant decrease in parahydroxyamphetamine excretion to 7.2 and 24.1% of vehicle control levels at 24 and 48 hours, respectively. command [3].
|
References |
[1]. Kehl SJ, et al. Quinidine-induced inhibition of the fast transient outward K+ current in rat melanotrophs. Br J Pharmacol. 1991 Jul;103(3):1807-13.
[2]. Roden DM, et al. Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramide. |
Molecular Formula |
C20H24N2O2.HBR
|
---|---|
Molecular Weight |
405.3287
|
CAS # |
549-49-5
|
Related CAS # |
Quinine;130-95-0;Quinine sulfate hydrate;6119-70-6;Quinine sulfate;549-56-4
|
SMILES |
C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@@H](C3=C4C=C(C=CC4=NC=C3)OC)O.Br
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4671 mL | 12.3356 mL | 24.6713 mL | |
5 mM | 0.4934 mL | 2.4671 mL | 4.9343 mL | |
10 mM | 0.2467 mL | 1.2336 mL | 2.4671 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.